Ménière’s Disease Treatments: A 30-Year Review

A major review of Ménière’s disease research reveals a troubling contradiction. While the volume and quality of studies have surged, the basic standards for reporting that research have collapsed. This “Quality Paradox” threatens to undermine real clinical progress made over the last three decades.

The findings come from a tri-decade scoping review led by Dr. Ofir Zavdy and colleagues at the University of Toronto. The team analyzed 257 studies from 1994 to 2024 to map trends in evidence and methodology for this complex inner ear disorder, defined by vertigo attacks, hearing loss, and tinnitus. Their work was published in *The Laryngoscope* [DOI: 10.1002/lary.70596, PMID: 42053150].

Mapping Three Decades of Ménière’s Research

The researchers systematically searched major medical databases for English-language clinical trials and prospective cohort studies involving adults. They graded each study using the Oxford Centre for Evidence-Based Medicine (CEBM) system, where Level 1 represents the strongest evidence (like large randomized trials) and Level 5 the weakest (expert opinion). Crucially, they also checked every study’s compliance with two key reporting standards: the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) guidelines for diagnosing Ménière’s and measuring treatment outcomes, and the CONSORT framework for transparent trial reporting.

This approach allowed the team to separate two questions: Is the research methodologically stronger? And is it being reported clearly and consistently? The answers were starkly different.

The Surge in Evidence and the Plunge in Standards

The analysis shows clear progress in the sheer weight of investigation. The number of high-quality Level 2 studies quadrupled, and Level 3 studies tripled over the review period. “Research volume surged,” the authors note, with statistically significant increases.

But this stronger evidence is being poorly communicated. Adherence to AAO-HNS diagnostic criteria fell to 73%. More alarmingly, only 34% of studies properly used the field’s established criteria to report treatment outcomes. This makes it difficult, if not impossible, to compare results across studies or to know if a new therapy truly works by the benchmarks the specialty itself has set. The decline in CONSORT compliance for trial reporting further obscures how studies were conducted.

A Clinical Shift Toward Preservation and Patents

Despite the reporting issues, the review identified clear trends in how Ménière’s disease is managed. The focus has moved decisively toward patient-centered, preservation-focused interventions. Destructive treatments, like intratympanic gentamicin to ablate vestibular function, are being overtaken by intratympanic steroid injections aimed at reducing inflammation without permanent damage.

The use of positive-pressure devices (like the Meniett device) has declined. Meanwhile, advanced imaging like hydrops-visualizing MRI is playing a larger role in diagnosis by directly showing the inner ear fluid buildup associated with the disease. There is also a noted increase in the use of cochlear implantation for patients with Ménière’s who progress to severe, untreatable hearing loss, reflecting a commitment to auditory rehabilitation.

Why the “Quality Paradox” Matters for Patients

For anyone living with Ménière’s disease, tinnitus, or hyperacusis, this research has direct implications. The shift toward gentler, preservation-focused care is positive and aligns with a broader trend in hearing and balance medicine toward personalized, less invasive management. You can read more about this holistic approach in our article on managing hyperacusis and tinnitus.

However, the declining reporting standards create a serious problem. When studies do not report outcomes consistently, it becomes harder for doctors to determine which treatments are truly most effective. It can slow down the adoption of good therapies and allow less effective ones to persist based on poorly presented data. This ultimately delays better care for patients.

A Call to Action for Stronger Science

Zavdy and his team conclude that the validity of recent advancements is at risk. They issue a clear recommendation: medical journals must enforce standardized reporting as a nonnegotiable requirement for publication. “To safeguard the evidence base,” they write, enforcement is essential.

This serves as a reminder that high-quality clinical care depends on both well-conducted *and* well-reported science. For patients, it underscores the importance of seeking care from specialists who base their practice on the highest levels of evidence and who participate in rigorous clinical research. As the field continues to advance, ensuring that progress is built on a solid, transparent foundation is the only way to guarantee that research translates into reliable patient benefit. The journey toward better Ménière’s management, as explored in our cross-site feature on understanding endolymphatic hydrops, depends on it.